• Kamada confirmed sufficient U.S. supply of KedRAB despite a CDC-cited year-over-year rise in rabies exposures and PEP use.
• Inventory and manufacturing capacity positioned to avoid disruption as utilization increases, supported by a vertically integrated supply chain.
• KedRAB is one of two FDA-approved human rabies immune globulin products in a U.S. market estimated at USD 200 million annually.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kamada Ltd. published the original content used to generate this news brief on September 17, 2026, and is solely responsible for the information contained therein.